This Article Full Text Full Text (PDF) All Versions of this Article: 0008-5472.CAN-08-0506v1 69/3/992    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Xie, T. Articles by Wei, M. L. Search for Related Content PubMed PubMed Citation Articles by Xie, T. Articles by Wei, M. L.

Multidrug Resistance Decreases with Mutations of Melanosomal Regulatory Genes

¹ Department of Dermatology, University of California-San Francisco; ² Veterans Affairs Medical Center-San Francisco, San Francisco, California

Requests for reprints: Maria L. Wei, 4150 Clement Street, VA 190, San Francisco, CA 94121. Phone: 415-221-4810, ext. 3365; Fax: 415-751-3927; E-mail: weim{at}derm.ucsf.edu.

Key Words: melanoma • cis-platin • vinblastine • etoposide • chemoresistance • melanosome • Hermansky-Pudlak syndrome • drug resistance • melanocyte • multidrug resistance

Whereas resistance to chemotherapy has long impeded effective treatment of metastatic melanoma, the mechanistic basis of this resistance remains unknown. One possible mechanism of drug resistance is alteration of intracellular drug distribution either by drug efflux or sequestration into intracellular organelles. Melanomas, as well as primary melanocytes from which they arise, have intracellular organelles, called melanosomes, wherein the synthesis and storage of the pigment melanin takes place. In this study, comparisons of congenic cells with and without functional molecules regulating melanosome formation show that sensitivity to the chemotherapeutic agent cis-diaminedichloroplatinum II (cis-platin) significantly increases with the mutation of genes regulating melanosome formation, concomitant disruption of melanosome morphology, and loss of mature melanosomes. Absence of the melanosomal structural protein gp100/Pmel17 causes increased cis-platin sensitivity. Independent mutations in three separate genes that regulate melanosome biogenesis (Dtnbp1, Pldn, Vps33a) also result in increased cis-platin sensitivity. In addition, a mutation of the gene encoding the integral melanosomal protein tyrosinase, resulting in aberrant melanosome formation, also causes increased cis-platin sensitivity. Furthermore, sensitivity to agents in other chemotherapeutic classes (e.g., vinblastine and etoposide) also increased with the mutation of Pldn. In contrast, a mutation in another melanosomal regulatory gene, Hps1, minimally affects melanosome biogenesis, preserves the formation of mature melanosomes, and has no effect on cis-platin or vinblastine response. Together, these data provide the first direct evidence that melanosomal regulatory genes influence drug sensitivity and that the presence of mature melanosomes likely contributes to melanoma resistance to therapy. [Cancer Res 2009;69(3):992–9]

This article has been cited by other articles:

				K. G. Chen, R. D. Leapman, G. Zhang, B. Lai, J. C. Valencia, C. O. Cardarelli, W. D. Vieira, V. J. Hearing, and M. M. Gottesman Influence of Melanosome Dynamics on Melanoma Drug Sensitivity J Natl Cancer Inst, September 16, 2009; 101(18): 1259 - 1271. [Abstract] [Full Text] [PDF]